Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma's First Reboost Vacc-4x Study Accepted for Publication in the Vaccine Journal

Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine. 

The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 available patients from previous study with the Company’s leading therapeutic HIV vaccine candidate Vacc-4x.  The study demonstrated that it is possible to elicit strong memory immune responses up to 7 years after the initial vaccination. 

 

 

If you would like to read more, visit Bionor Pharam's website here.

Associated companies:


Related news

Latest news

Chairman of IACS pinpoints three key themes of the Association’s strategy for the future

Commenting on the publication of the 2017 Annual Review, 

DNV GL launches alternative fuels white paper

For newbuilding vessels,

MINSHIP Shipmanagement boosts digitalization with DNV GL

MINSHIP is optimizing processes as they are managing a growing fleet. 

The fully electric Future of The Fjords has been launched

The new build is 42m long, 

Winner of Norwegian Export Award 2018 Announced

Airthings is the winner of the Norwegian Export Award 2018. 

Why going in circles is good

In fire detection systems for explosive environments,

Here is AKVA group’s first hybrid feed barge!

Protecting the environment is our main reason to invest in this technology. 

New Display Technologies Enable the Naval Vessel Bridges of the Future

Hatteland Display's cutting-edge display solutions on show at Sea-Air-Space 2018 enable a new data-centric approach to vessel and strategic operations.

Steinsvik Group and Aqualine – collaborating on future solutions

Aqualine is a R&D cage system supplier of cages,